Treatment of neuroendocrine tumours with <superscript>177</superscript>Lu‐peptide receptor radionuclide therapy: Challenging clinical scenarios and their management.
In: Journal of Neuroendocrinology, Jg. 34 (2022-04-01), Heft 4, S. 1-8
Online
academicJournal
Zugriff:
Peptide receptor radionuclide therapy (PRRT) for the treatment of patients with neuroendocrine tumours is usually well tolerated, with selection based on existing guidelines. However, there are various scenarios where the risk–benefit analysis of PRRT needs to be evaluated to limit any complications associated with PRRT. This review looks at 11 key scenarios where the risk–benefit of PRRT needs to be closely evaluated. [ABSTRACT FROM AUTHOR]
| Titel: |
Treatment of neuroendocrine tumours with <superscript>177</superscript>Lu‐peptide receptor radionuclide therapy: Challenging clinical scenarios and their management.
|
|---|---|
| Autor/in / Beteiligte Person: | Navalkissoor, Shaunak ; Toumpanakis, Christos ; Caplin, Martyn ; Gnanasegaran, Gopinath |
| Link: | |
| Zeitschrift: | Journal of Neuroendocrinology, Jg. 34 (2022-04-01), Heft 4, S. 1-8 |
| Veröffentlichung: | 2022 |
| Medientyp: | academicJournal |
| ISSN: | 0953-8194 (print) |
| DOI: | 10.1111/jne.13088 |
| Schlagwort: |
|
| Sonstiges: |
|